Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Alzheimer's disease begins with a long period during which abnormal amyloid and tau proteins build up in the brain without ...
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due ...
Independence Blue Cross has instituted an 18-month benefit exclusion on certain drugs that receive accelerated approval from ...
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...
There’s intriguing news today about a technology that could improve treatment in people with Alzheimer’s. It uses sound waves ...
For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...
Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...
Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...
Delve into the challenges Black Americans face with Alzheimer’s and the urgent need for better prevention, care, and ...